

Investor Relations  
(2023.05)

**PharmAbcine**

ANTIBODY  
THERAPEUTICS  
FOR LIFE

## Disclaimer

This document has been prepared by PharmAbcine Co., Ltd. (hereafter, the “Company”) to provide information on presentations to institutional investors regarding the proposed.

“Forecast information” in this document is information that has not been subject to an individual verification. The forecast is related to future events, not the past, which means the Company’s future management status and financial performance. In terms of expression, it includes words such as “forecast,” “prospect,” “plan,” “expectation,” and “(E).”

The above “forecast information” is influenced by future changes in management environment and inherently subject to uncertainties that may result in significant discrepancies between actual future performance and what is stated or implied in “forecast information.”

Furthermore, the prospect is based on the presentation date, considering the present market conditions and the direction of the Company's management. Please be aware that changes may occur without notice due to changes in the market environment and strategies.

Please note that the Company and its employees are not liable for any loss or damage incurred in connection with the use of this document, including negligence or otherwise.

This document does not constitute any solicitation for offers, sales, trading, or subscription of stock, and any part of this document cannot be the basis for the relevant contracts, arrangements, or investment decisions.

Please note that this material may be used for Preprofit purposes without content modification (however, source representation is required), and unauthorized distribution and reproduction of materials with modified content without prior approval of the Company may result in legal sanctions.

# About PharmAbcine

A clinical-stage biotech company that aims to develop next-generation antibody therapeutics

## ● Company Outline

|                           |                                                                                                                  |
|---------------------------|------------------------------------------------------------------------------------------------------------------|
| <b>Name</b>               | PharmAbcine                                                                                                      |
| <b>Establishment</b>      | Sep 3, 2008 (IPO in Nov 21, 2018)                                                                                |
| <b>Business Area</b>      | Antibody Therapeutics                                                                                            |
| <b>Stock Ticker</b>       | KOSDAQ: 208340ks                                                                                                 |
| <b>No. of Employee</b>    | 50 (As of May, 2023)                                                                                             |
| <b>Oversea Subsidiary</b> | Wincal BioPharm (South San Francisco, U.S)<br>PharmAbcine Australia Pty. Ltd.<br>(Brisbane City, QLD, Australia) |

## ● CEO Profile



**Jin-San Yoo**  
President/CEO

- CEO/President/Founder of PharmAbcine
- MAB Expert, EDQM/EU
- Board, Drug Review Committee/MFDS
- Board, Strategic Planning Committee/MFDS
- BOD, BioHealthcare Association
- Head of The Therapeutic Antibody Center(TTAC) at KRIBB
- Head of Therapeutic Antibody Division(TAD) at LG Chem (LGLS)
- Senior Associate at The Scripps Research Institute

## Differentiating Factors



### Scientific Reference

- Marquee investors, including Novartis and OrbiMed



### Robust R&D Platform

- HuPhage Display Library with  $10^{11}$  fully human antibodies
- Lead molecule in Phase II clinical stage
- Multiple first-in-class assets about to enter clinical stage



### Global Partnerships


- Collaboration with MSD, Sanofi, Roche, and U.S NIH
- Clinical studies with world-class hospitals and experts



### Seasoned Management

- Leadership with extensive drug development experience
- SAB consisting of global key opinion leaders

## A fully human antibody technology platform for generation of mono & multi-specific antibodies



# Pipeline Overview

| Molecules                         | Mode of Action               | Indications             | Lead Compound | Preclinical | Phase I                 | Phase II                     | Phase III |
|-----------------------------------|------------------------------|-------------------------|---------------|-------------|-------------------------|------------------------------|-----------|
| Olinvacimab<br>+<br>Pembrolizumab | anti-VEGFR2<br>+<br>anti-PD1 | mTNBC                   | Australia     |             |                         |                              |           |
| PMC-403                           | TIE2 activator               | Ocular diseases         | Korea         |             |                         | IND Approval in May 2023     |           |
| PMC-309                           | anti-VISTA                   | Solid tumors            | Australia     |             | Phase I in Preparation  | First-in-class<br>candidates |           |
| PMC-403                           | TIE2 activator               | Solid tumors            |               |             | Preclinical in progress |                              |           |
|                                   |                              | SCLS (Clarkson disease) |               |             | Phase I in Preparation  |                              |           |
| PMC-402                           | TIE2 activator               | DPN                     |               |             | Phase I in Preparation  |                              |           |

## Multiple early-stage candidates are in development

### Monoclonal Antibody

PMC-401s (anti-ANG2 scFv)

\* Ocular diseases (i.e. AMD and DR)

PMC-401 (anti-ANG2)

\* IO drug-resistant tumor

PMC-xxx

\* Multiple next generation oncology/IO Abs

### Bispecific Antibody

PMC-122 (anti-PD-L1/CD47, Sirp- $\alpha$ )

\* Solid tumors (IO)

PMC-201 (anti-VEGFR2/DLL4)

\* Solid tumors

PMC-001 (anti-VEGFR2/TIE2)

\* Solid tumors

### CAR-T/CAR-NK/Biosimilar

PMC-005BL (anti-EGFRvIII)

\* Tumor (CAR-T/CAR-NK/RIT)


PMC-901 (anti-VEGF-A)

\* Avastin biosimilar


PMC-902 (anti-VEGF/PIGF)

\* Eylea biosimilar

## Pipeline Expansion History



# Long-term Growth Strategy



- Monoclonal antibody
- Bispecific antibody

- Initiate clinical trials for the main pipelines
- Seek licensing deals for early assets

- Monoclonal antibody
- Bispecific antibody
- Cell therapies (Co-development)

- Sign licensing deals with global pharmas
- Expand clinical indications for existing molecules
- Develop additional IO candidates with novel target
- Seek licensing deals for early assets
- Prepare to launch CRO services

- Monoclonal antibody
- Bispecific antibody
- Cell therapies (Co-development)

- Generate revenues through milestone developments
- Seek licensing deals for early assets
- Offer biopanning services to global biotechs
- Generate revenues from CRO services

ANTIBODY  
THERAPEUTICS  
FOR LIFE

**PharmAbcine**

## Appendices

- Accomplishments
- Management team
- Scientific Advisory Board & Consultants
- R&D platform expansion through U.S subsidiary
- Accelerating growth of the antibody therapeutics market
- Rising popularity in combo therapies
- About mTNBC
- About rGBM
- Glossary

# Accomplishments

2008~2013

Foundation

- 2013.03 Out-Licensing of 1E4 mAb
- 2012.11 Research Collaboration with Sanofi-Aventis
- 2008.10 Grand Prix from 1st GATE Project by Novartis
- 2008.09 Establishment of PharmAbcine Inc.

2014~2017

Proof of Competitiveness by  
Out-Licensing

- 2016.06 Award from MFDS
- 2014.10 Out-Licensing of Olinvacimab (All indications, China/Korea Only)
- 2014.07 Out-Licensing of PMC-001 (All indications, China/Korea excluded)
- 2014.03 Out-Licensing of Olinvacimab (Eye diseases)

2018~

R&D Empowerment  
by Research Collaboration

- 2022.02 Phase Ib Olinvacimab-Pembrolizumab trial in mTNBC completed
- 2021.10 Phase Ib Olinvacimab-Pembrolizumab trial in rGBM completed
- 2021.09 HREC approval for phase II Olinvacimab-Pembrolizumab trial in mTNBC
- 2020.12 Interim result of Olinvacimab-Pembrolizumab combo trial for mTNBC presented
- 2020.01 Establishment of a subsidiary in U.S., WINCAL BioPharm
- 2018.11 Establishment of a subsidiary in Australia
- 2018.11 KOSDAQ IPO
- 2018.09 Olinvacimab Phase II IND Approval for Avastin refractory rGBM patients from US FDA
- 2018.03 ODD Approval of Olinvacimab for GBM from US FDA
- 2018.01 Clinical Research Collaboration with MSD for Combo Trials

## Management team



**Weon Sup Lee**  
Head of R&D Center

- Commendation from MSIFP
- PI of the Best Project of the Year
- PharmAbcine
- Post-Doc. KRIBB
- Post-Doc. SUNY
- Ph.D., KAIST



**Hang-Rae Kim**  
M.D, Ph.D

- Professor, Seoul Nat. University
- Visiting Professor, Yale University
- Post-Doc. Yale University
- Sr. Scientist, Bioneer Corporation
- Ph.D, Seoul University



**Du Yung Jung**  
Auditing Director

- Business Development, Shinhan Bank
- Investment & Finance, Johong Bank
- Int. Finance, Hyundai Financial
- MBA, Pennsylvania Univ. Wharton School

# Scientific Advisory Board (SAB) & Consultants

## SAB



### Napoleone Ferrara

Moore's Cancer Center, UC San Diego

- Senior Deputy Director for Basic Science
- Distinguished Professor of Pathology at UCSD School of Medicine
- Distinguished Adjunct Professor of Ophthalmology and Pharmacology at UCSD
- Inventor of Avastin® and Lucentis®
- Pioneer of the Angiogenesis Therapy in Oncology and Ophthalmology



### Quan Dong Nguyen

Byers Eye Institute, Stanford University

- Professor of Ophthalmology and Professor of Pediatrics, Stanford University School of Medicine
- Led clinical trials evaluating Eylea® for neovascular AMD and Lucentis® for DME, which served as the foundation for subsequent trials and FDA approval of anti-VEGF therapy
- Principal Investigator on multiple clinical trials in ophthalmology sponsored by the National Eye Institute and other organizations



### David Cheresh

Moore's Cancer Center, UC San Diego

- Distinguished Professor and Vice Chair of Research, Department of Pathology
- Director for Translational Research at UCSD Moore's Cancer Center
- Inventor of Unituxin® and Vitaxin®
- Outstanding Investigator Award from NCI
- MERIT Award from both NIH and NCI



### Soo Hyun Lee

Korea University Medical Center

- Professor, Division of Hematology-Oncology at KUMC
- Country Medical Director at Celgene
- Korea Oncology Medical Lead at Pfizer
- Medical Oncologist at Severance Medical Center

## Consultants



### Robert S. Kerbel

Sunnybrook Research Institute, University of Toronto

- Canada Research Chair (1 Tier) in Tumor Biology, Angiogenesis and Antiangiogenic Therapy
- Professor, Medical Biophysics, University of Toronto
- Senior Scientist, Sunnybrook Health Sciences Center
- Director, Cancer Research Labs, Queen's University



### Do Hyun Nam

Samsung Medical Center

- Chairman of SMCIRC
- Professor at Sung Kyun Kwan Univ.
- PI at Cancer Stem Cell Research Center at SMC
- QA Clinic Center at SMC
- Seoul National University School of Medicine (MD/Ph.D)

## R&D platform expansion through U.S subsidiary

### Unlocking the full potential value of PharmAbcine's antibody discovery platform



**TaeWon Lee**  
CSO (WINCAL)

- CoFounder of WINCAL BioPharm
- Program Leader, Amgen
- Research Scientist, Theravance Biopharma
- Post-Doc. Stanford
- Ph.D., University of Glasgow



- A 100% owned US subsidiary located in South San Francisco, USA



- Staffed mostly with former Amgen R&D professionals




- Focusing on next-gen eye drop formulation therapeutics for AMD and DR and novel therapeutics for vascular diseases including aneurysm



- To unlock the full potential value of our pipeline assets and antibody discovery platform and provide a growth engine

# Why invest in antibody therapeutics?

## Highly successful growth of the antibody therapeutics market





# ANTIBODY THERAPEUTICS FOR LIFE

**PharmAbcine**



2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil, Yuseong-gu,  
Daejeon, Republic of Korea



IR Rep. Jin-San Yoo, Head  
jinsan.yoo@pharmabcine.com



IR Inquiry Sookyoung Shin, Manager  
sookyoung.shin@pharmabcine.com